CliffBio
biologic

Anktiva

nogapendekin alfa inbakicept-pmln

Loss of exclusivityApril 2036projected — 12-year biologic exclusivity estimate
CompanyAltor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.

Drug detail

Brand nameAnktiva
Active ingredientnogapendekin alfa inbakicept-pmln
Strength400MCG/0.4ML
Dosage formSolution
RouteIntravesical
ModalityBiologic
FDA approvalApril 2024
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Anktiva patent cliff — loss of exclusivity April 2036 | CliffBio